BC Week In Review | Jan 15, 2007
Company News

Abbott, Boston Scientific sales and marketing update

BSX launched the Promus everolimus-eluting coronary stent system to treat coronary artery disease (CAD) in Europe and selected Asian and Latin American markets. ABT manufactures the stent and supplies it to BSX under a 2006...
BC Week In Review | Oct 23, 2006
Clinical News

Promus regulatory update

BSX received CE Mark approval for Promus, an everolimus-eluting coronary stent system, to treat coronary artery disease (CAD). BSX expects to launch the product in Europe next year. ABT manufactures the stent and distributes it...
BC Week In Review | Oct 16, 2006
Company News

Endocyte management update

Endocyte Inc. , West Lafayette, Ind.   Business: Cancer, Drug delivery   Hired: Michael Sherman as CFO, formerly VP of finance and strategic planning at Guidant Corp.  ...
BioCentury | Oct 9, 2006
Finance

Ebb & Flow

Biotech had a good first week of the quarter, reflected by a 3.4% jump in the BioCentury 100 Index on the back of biotech-to-biotech M&A news and robust after-market support for companies issuing new paper....
BC Week In Review | Sep 18, 2006
Company News

Bristol-Myers management update

Bristol-Myers Squibb Co. (BMY), New York, N.Y.   Business: Pharmaceuticals   Departed: Peter Dolan as CEO and Richard Willard as SVP and general counsel; James Cornelius, chairman emeritus of Guidant Corp. and a director at...
BC Week In Review | Sep 18, 2006
Company News

Endocyte board of directors update

Endocyte Inc. , West Lafayette, Ind.   Business: Cancer, Drug delivery   Appointed: Keith Brauer, former VP of finance and CFO at Guidant Corp.  ...
BC Extra | Sep 13, 2006
Top Story

Dolan leaves Bristol-Myers

BMY said Peter Dolan left his position as CEO after former federal judge Frederick Lacey urged the board to terminate Dolan's employment. James Cornelius, a BMY director and chairman emeritus of Guidant (GDT), will act...
BC Week In Review | May 1, 2006
Company News

Abbott, Boston Scientific deal

ABT acquired the vascular business of BSX's Guidant Corp. unit for $4.1 billion in cash. ABT also will purchase $1.4 billion of BSX stock, which is less than a 5% stake in the company. BSX...
BC Extra | Apr 19, 2006
Financial News

JNJ beats Street EPS

Johnson & Johnson (JNJ) posted first quarter adjusted diluted EPS of $0.99, beating the Street by a penny and up 5% from $0.94 in the first quarter of 2005. The adjusted figure excludes a gain...
BC Week In Review | Mar 13, 2006
Clinical News

Everolimus stent: Pilot trial started

GDT started the ABSORB trial in up to 60 patients to treat CAD. Safety will be measured by the occurrence of major adverse cardiac events (MACE) and stent thrombosis rate monitoring. An initial assessment will...
Items per page:
1 - 10 of 98
BC Week In Review | Jan 15, 2007
Company News

Abbott, Boston Scientific sales and marketing update

BSX launched the Promus everolimus-eluting coronary stent system to treat coronary artery disease (CAD) in Europe and selected Asian and Latin American markets. ABT manufactures the stent and supplies it to BSX under a 2006...
BC Week In Review | Oct 23, 2006
Clinical News

Promus regulatory update

BSX received CE Mark approval for Promus, an everolimus-eluting coronary stent system, to treat coronary artery disease (CAD). BSX expects to launch the product in Europe next year. ABT manufactures the stent and distributes it...
BC Week In Review | Oct 16, 2006
Company News

Endocyte management update

Endocyte Inc. , West Lafayette, Ind.   Business: Cancer, Drug delivery   Hired: Michael Sherman as CFO, formerly VP of finance and strategic planning at Guidant Corp.  ...
BioCentury | Oct 9, 2006
Finance

Ebb & Flow

Biotech had a good first week of the quarter, reflected by a 3.4% jump in the BioCentury 100 Index on the back of biotech-to-biotech M&A news and robust after-market support for companies issuing new paper....
BC Week In Review | Sep 18, 2006
Company News

Bristol-Myers management update

Bristol-Myers Squibb Co. (BMY), New York, N.Y.   Business: Pharmaceuticals   Departed: Peter Dolan as CEO and Richard Willard as SVP and general counsel; James Cornelius, chairman emeritus of Guidant Corp. and a director at...
BC Week In Review | Sep 18, 2006
Company News

Endocyte board of directors update

Endocyte Inc. , West Lafayette, Ind.   Business: Cancer, Drug delivery   Appointed: Keith Brauer, former VP of finance and CFO at Guidant Corp.  ...
BC Extra | Sep 13, 2006
Top Story

Dolan leaves Bristol-Myers

BMY said Peter Dolan left his position as CEO after former federal judge Frederick Lacey urged the board to terminate Dolan's employment. James Cornelius, a BMY director and chairman emeritus of Guidant (GDT), will act...
BC Week In Review | May 1, 2006
Company News

Abbott, Boston Scientific deal

ABT acquired the vascular business of BSX's Guidant Corp. unit for $4.1 billion in cash. ABT also will purchase $1.4 billion of BSX stock, which is less than a 5% stake in the company. BSX...
BC Extra | Apr 19, 2006
Financial News

JNJ beats Street EPS

Johnson & Johnson (JNJ) posted first quarter adjusted diluted EPS of $0.99, beating the Street by a penny and up 5% from $0.94 in the first quarter of 2005. The adjusted figure excludes a gain...
BC Week In Review | Mar 13, 2006
Clinical News

Everolimus stent: Pilot trial started

GDT started the ABSORB trial in up to 60 patients to treat CAD. Safety will be measured by the occurrence of major adverse cardiac events (MACE) and stent thrombosis rate monitoring. An initial assessment will...
Items per page:
1 - 10 of 98